Successful treatment of secondary graft failure after allogeneic stem cell transplantation for aplastic anemia with eltrombopag

  • TAKANO Kosuke
    Division of Hematology, National Defense Medical College Hospital
  • IZUMI Takuya
    Division of Hematology, National Defense Medical College Hospital
  • KAWAMURA Toshikuni
    Division of Hematology, National Defense Medical College Hospital
  • HORIUCHI Toshikatsu
    Department of Internal Medicine, Irumagawa Hospital
  • KOBAYASHI Shinichi
    Division of Hematology, National Defense Medical College Hospital
  • SATO Ken
    Fourth Department of Internal Medicine, Teikyo University School of Medicine, Mizonokuchi Hospital
  • KIMURA Fumihiko
    Division of Hematology, National Defense Medical College Hospital

Bibliographic Information

Other Title
  • 同種造血幹細胞移植後の二次性生着不全に対してeltrombopagが奏効した再生不良性貧血
  • ドウシュ ゾウケツ カンサイボウ イショク ゴ ノ ニジセイセイチャク フゼン ニ タイシテ eltrombopag ガ ソウコウ シタ サイセイ フリョウセイ ヒンケツ

Search this article

Abstract

<p>Herein we report a case of successful treatment of secondary graft failure due to poor graft function (PGF) using eltrombopag. A 25-year-old woman with aplastic anemia (stage 3) underwent allogeneic bone marrow transplantation (BMT) from her HLA-matched brother. Neutrophil engraftment was achieved on day 17, but she remained dependent on platelet transfusion. Chimerism analysis showed complete donor type, but she also became dependent on red blood cell transfusion later. Eltrombopag was administered on day 253 after BMT, after which she exhibited hematopoietic recovery, resulting in the withdrawal of transfusion dependency. Blood counts continued to be stable after eltrombopag was discontinued. The use of eltrombopag enabled outpatient treatment and induced hematopoietic recovery without significant side effects. Eltrombopag may be an effective and safe option for PGF after BMT.</p>

Journal

  • Rinsho Ketsueki

    Rinsho Ketsueki 63 (3), 177-181, 2022

    The Japanese Society of Hematology

Details 詳細情報について

Report a problem

Back to top